Dataset Information

A Similarity Regression Fusion Model for Integrating Multi-Omics Data to Identify Cancer Subtypes.

ABSTRACT: The identification of cancer subtypes is crucial to cancer diagnosis and treatments. A number of methods have been proposed to identify cancer subtypes by integrating multi-omics data in recent years. However, the existing methods rarely consider the biases of similarity between samples and weights of different omics data in integration. More accurate and flexible integration approaches need to be developed to comprehensively investigate cancer subtypes. In this paper, we propose a simple and flexible similarity fusion model for integrating multi-omics data to identify cancer subtypes. We consider the similarity biases between samples in each omics data and predict corrected similarities between samples using a generalized linear model. We integrate the corrected similarity information from multi-omics data according to different data-view weights. Based on the integrative similarity information, we cluster patient samples into different subtype groups. Comprehensive experiments demonstrate that the proposed approach obtains more significant results than the state-of-the-art integrative methods. In conclusion, our approach provides an effective and flexible tool to investigate subtypes in cancer by integrating multi-omics data.

SUBMITTER: Guo Y

PROVIDER: S-EPMC6070922 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A Similarity Regression Fusion Model for Integrating Multi-Omics Data to Identify Cancer Subtypes.

Guo Yang Y Zheng Jianning J Shang Xuequn X Li Zhanhuai Z

Genes 20180621 7

The identification of cancer subtypes is crucial to cancer diagnosis and treatments. A number of methods have been proposed to identify cancer subtypes by integrating multi-omics data in recent years. However, the existing methods rarely consider the biases of similarity between samples and weights of different omics data in integration. More accurate and flexible integration approaches need to be developed to comprehensively investigate cancer subtypes. In this paper, we propose a simple and fl ...[more]

PMID: 29933539

Similar Datasets

Project description:Childhood asthma is one of the most common respiratory diseases with rising mortality and morbidity. The multi-omics data is providing a new chance to explore collaborative biomarkers and corresponding diagnostic models of childhood asthma. To capture the nonlinear association of multi-omics data and improve interpretability of diagnostic model, we proposed a novel deep association model (DAM) and corresponding efficient analysis framework. First, the Deep Subspace Reconstruction was used to fuse the omics data and diagnostic information, thereby correcting the distribution of the original omics data and reducing the influence of unnecessary data noises. Second, the Joint Deep Semi-Negative Matrix Factorization was applied to identify different latent sample patterns and extract biomarkers from different omics data levels. Third, our newly proposed Deep Orthogonal Canonical Correlation Analysis can rank features in the collaborative module, which are able to construct the diagnostic model considering nonlinear correlation between different omics data levels. Using DAM, we deeply analyzed the transcriptome and methylation data of childhood asthma. The effectiveness of DAM is verified from the perspectives of algorithm performance and biological significance on the independent test dataset, by ablation experiment and comparison with many baseline methods from clinical and biological studies. The DAM-induced diagnostic model can achieve a prediction AUC of 0.912, which is higher than that of many other alternative methods. Meanwhile, relevant pathways and biomarkers of childhood asthma are also recognized to be collectively altered on the gene expression and methylation levels. As an interpretable machine learning approach, DAM simultaneously considers the non-linear associations among samples and those among biological features, which should help explore interpretative biomarker candidates and efficient diagnostic models from multi-omics data analysis for human complex diseases.

Project description:With the rapid development of multi-omics technologies and accumulation of large-scale bio-datasets, many studies have conducted a more comprehensive understanding of human diseases and drug sensitivity from multiple biomolecules, such as DNA, RNA, proteins and metabolites. Using single omics data is difficult to systematically and comprehensively analyze the complex disease pathology and drug pharmacology. The molecularly targeted therapy-based approaches face some challenges, such as insufficient target gene labeling ability, and no clear targets for non-specific chemotherapeutic drugs. Consequently, the integrated analysis of multi-omics data has become a new direction for scientists to explore the mechanism of disease and drug. However, the available drug sensitivity prediction models based on multi-omics data still have problems such as overfitting, lack of interpretability, difficulties in integrating heterogeneous data, and the prediction accuracy needs to be improved. In this paper, we proposed a novel drug sensitivity prediction (NDSP) model based on deep learning and similarity network fusion approaches, which extracts drug targets using an improved sparse principal component analysis (SPCA) method for each omics data, and construct sample similarity networks based on the sparse feature matrices. Furthermore, the fused similarity networks are put into a deep neural network for training, which greatly reduces the data dimensionality and weakens the risk of overfitting problem. We use three omics of data, RNA sequence, copy number aberration and methylation, and select 35 drugs from Genomics of Drug Sensitivity in Cancer (GDSC) for experiments, including Food and Drug Administration (FDA)-approved targeted drugs, FDA-unapproved targeted drugs and non-specific therapies. Compared with some current deep learning methods, our proposed method can extract highly interpretable biological features to achieve highly accurate sensitivity prediction of targeted and non-specific cancer drugs, which is beneficial for the development of precision oncology beyond targeted therapy.

Dataset Information

A Similarity Regression Fusion Model for Integrating Multi-Omics Data to Identify Cancer Subtypes.

Publications

A Similarity Regression Fusion Model for Integrating Multi-Omics Data to Identify Cancer Subtypes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets